228 related articles for article (PubMed ID: 28329685)
1. Critical Role for GAB2 in Neuroblastoma Pathogenesis through the Promotion of SHP2/MYCN Cooperation.
Zhang X; Dong Z; Zhang C; Ung CY; He S; Tao T; Oliveira AM; Meves A; Ji B; Look AT; Li H; Neel BG; Zhu S
Cell Rep; 2017 Mar; 18(12):2932-2942. PubMed ID: 28329685
[TBL] [Abstract][Full Text] [Related]
2. LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis.
Zhu S; Zhang X; Weichert-Leahey N; Dong Z; Zhang C; Lopez G; Tao T; He S; Wood AC; Oldridge D; Ung CY; van Ree JH; Khan A; Salazar BM; Lummertz da Rocha E; Zimmerman MW; Guo F; Cao H; Hou X; Weroha SJ; Perez-Atayde AR; Neuberg DS; Meves A; McNiven MA; van Deursen JM; Li H; Maris JM; Look AT
Cancer Cell; 2017 Sep; 32(3):310-323.e5. PubMed ID: 28867147
[TBL] [Abstract][Full Text] [Related]
3. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
4. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.
Zhu S; Lee JS; Guo F; Shin J; Perez-Atayde AR; Kutok JL; Rodig SJ; Neuberg DS; Helman D; Feng H; Stewart RA; Wang W; George RE; Kanki JP; Look AT
Cancer Cell; 2012 Mar; 21(3):362-73. PubMed ID: 22439933
[TBL] [Abstract][Full Text] [Related]
5.
Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
[TBL] [Abstract][Full Text] [Related]
6. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest.
Yaari S; Jacob-Hirsch J; Amariglio N; Haklai R; Rechavi G; Kloog Y
Clin Cancer Res; 2005 Jun; 11(12):4321-30. PubMed ID: 15958613
[TBL] [Abstract][Full Text] [Related]
7. A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma.
Cheung BB; Kleynhans A; Mittra R; Kim PY; Holien JK; Nagy Z; Ciampa OC; Seneviratne JA; Mayoh C; Raipuria M; Gadde S; Massudi H; Wong IPL; Tan O; Gong A; Suryano A; Diakiw SM; Liu B; Arndt GM; Liu T; Kumar N; Sangfelt O; Zhu S; Norris MD; Haber M; Carter DR; Parker MW; Marshall GM
Oncogene; 2021 Apr; 40(13):2367-2381. PubMed ID: 33658627
[TBL] [Abstract][Full Text] [Related]
8. GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma.
Dong Z; Yeo KS; Lopez G; Zhang C; Dankert Eggum EN; Rokita JL; Ung CY; Levee TM; Her ZP; Howe CJ; Hou X; van Ree JH; Li S; He S; Tao T; Fritchie K; Torres-Mora J; Lehman JS; Meves A; Razidlo GL; Rathi KS; Weroha SJ; Look AT; van Deursen JM; Li H; Westendorf JJ; Maris JM; Zhu S
Cancer Res; 2021 Jun; 81(11):2995-3007. PubMed ID: 33602789
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma.
Yu Y; Ding J; Zhu S; Alptekin A; Dong Z; Yan C; Zha Y; Ding HF
Cell Death Dis; 2021 Aug; 12(9):821. PubMed ID: 34462431
[TBL] [Abstract][Full Text] [Related]
10. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
11. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.
Petroni M; Veschi V; Prodosmo A; Rinaldo C; Massimi I; Carbonari M; Dominici C; McDowell HP; Rinaldi C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Soddu S; Giannini G
Mol Cancer Res; 2011 Jan; 9(1):67-77. PubMed ID: 21173028
[TBL] [Abstract][Full Text] [Related]
12. Neuroblastoma and Its Zebrafish Model.
Zhu S; Thomas Look A
Adv Exp Med Biol; 2016; 916():451-78. PubMed ID: 27165366
[TBL] [Abstract][Full Text] [Related]
13. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
Ruess DA; Heynen GJ; Ciecielski KJ; Ai J; Berninger A; Kabacaoglu D; Görgülü K; Dantes Z; Wörmann SM; Diakopoulos KN; Karpathaki AF; Kowalska M; Kaya-Aksoy E; Song L; van der Laan EAZ; López-Alberca MP; Nazaré M; Reichert M; Saur D; Erkan MM; Hopt UT; Sainz B; Birchmeier W; Schmid RM; Lesina M; Algül H
Nat Med; 2018 Jul; 24(7):954-960. PubMed ID: 29808009
[TBL] [Abstract][Full Text] [Related]
14. Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis.
Carter DR; Sutton SK; Pajic M; Murray J; Sekyere EO; Fletcher J; Beckers A; De Preter K; Speleman F; George RE; Haber M; Norris MD; Cheung BB; Marshall GM
Mol Oncol; 2016 Jun; 10(6):866-78. PubMed ID: 26996379
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.
Chesler L; Goldenberg DD; Collins R; Grimmer M; Kim GE; Tihan T; Nguyen K; Yakovenko S; Matthay KK; Weiss WA
Neoplasia; 2008 Nov; 10(11):1268-74. PubMed ID: 18953436
[TBL] [Abstract][Full Text] [Related]
16. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
[TBL] [Abstract][Full Text] [Related]
17. Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis.
Lopez-Delisle L; Pierre-Eugène C; Louis-Brennetot C; Surdez D; Raynal V; Baulande S; Boeva V; Grossetête-Lalami S; Combaret V; Peuchmaur M; Delattre O; Janoueix-Lerosey I
Oncogene; 2018 Mar; 37(11):1417-1429. PubMed ID: 29321660
[TBL] [Abstract][Full Text] [Related]
18. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
[TBL] [Abstract][Full Text] [Related]
19. The pre-rRNA processing factor DEF is rate limiting for the pathogenesis of MYCN-driven neuroblastoma.
Tao T; Sondalle SB; Shi H; Zhu S; Perez-Atayde AR; Peng J; Baserga SJ; Look AT
Oncogene; 2017 Jul; 36(27):3852-3867. PubMed ID: 28263972
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.
Chesler L; Schlieve C; Goldenberg DD; Kenney A; Kim G; McMillan A; Matthay KK; Rowitch D; Weiss WA
Cancer Res; 2006 Aug; 66(16):8139-46. PubMed ID: 16912192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
